The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

Anthropic (ANTHRO) has acquired Coefficient Bio, a biotech focused on developing AI models for biological research, for slightly more than $400M, according to The Information and a report from Eric ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Anthropic has acquired Coefficient Bio, a stealth biotech startup with fewer than 10 people, for $400 million in stock. The ...

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...